The kidney and cardiovascular outcome trials

Area of Science:

• Nephrology and Endocrinology
• Cardiovascular Medicine
• Pharmacology

Background:

• Chronic kidney disease (CKD) is prevalent in type 2 diabetes (T2D), affecting nearly 20% of patients with Stage 3 or worse disease.
• Traditional glycemic control and blood pressure management have shown benefits, but newer agents offer additional renal protection.
• Cardiovascular outcome trials (CVOTs) with newer T2D therapies provide insights into renal outcomes independent of glycemic control.

Discussion:

• Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, lixisenatide, semaglutide) demonstrate reductions in albuminuria and may benefit patients with Stage 3 CKD.
• Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., saxagliptin) also show improvements in albuminuria, irrespective of renal function or glycemic control.
• Sodium-glucose cotransporter (SGLT) 2 inhibitors (e.g., canagliflozin, empagliflozin) exhibit dual effects, reducing albuminuria progression and potentially slowing estimated glomerular filtration rate (eGFR) decline, while also decreasing acute kidney injury.

Key Insights:

• GLP-1 receptor agonists significantly reduced albuminuria in trials like LEADER, ELIXA, and SUSTAIN-6.
• DPP-4 inhibitors, notably saxagliptin, improved microalbumin levels in the SAVOR-TIMI 53 trial.
• SGLT2 inhibitors demonstrated substantial reductions in albuminuria progression and renal event rates in CANVAS and EMPA-REG OUTCOME trials.

Outlook:

• Emerging evidence suggests T2D treatments can achieve cardiovascular and renal benefits beyond HbA1c reduction.
• GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors represent a promising therapeutic avenue for managing CKD in T2D.
• Future research should continue to explore the long-term renal protective effects of these novel diabetes medications.